Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients

NCT04762628 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19

Interventions

DIETARY_SUPPLEMENT: MAF capsules 148 mg
DIETARY_SUPPLEMENT: M capsules 148 mg
OTHER: Standard of care

Sponsor

Saisei Pharma